Efficacy of Short-Term High-Dose Atorvastatin for Prevention of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography
Efficacy of Short-Term High-Dose Atorvastatin for Prevention of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography
复制标题
DOI：
10.1177/0003319710364216
复制
发表时间：
2010-10-01
期刊：
影响因子：
2.8
通讯作者：
Alemdar, Recai
中科院分区：
文献类型：
--
作者：
Ozhan, Hakan;Erden, Ismail;Alemdar, Recai
造影剂肾病（CIN）与发病率增加、住院时间延长和费用增加相关。我们比较了阿托伐他汀加N-乙酰半胱氨酸（NAC）方案与NAC单药治疗行冠状动脉造影的患者。共研究了130例接受冠状动脉造影术的患者（平均年龄54 ± 10岁; 77例男性）。NAC组发生7例CIN，阿托伐他汀+ NAC组发生2例;差异不显著。两组之间的基线平均肌酐和估计肾小球滤过率（eGFR）相似，而在手术后，阿托伐他汀+ NAC组的肌酐显著降低，eGFR升高。肌酐变化（基线肌酐-术后肌酐）在服用他汀类药物加NAC的患者中也显著较高。阿托伐他汀可有效保护接受冠状动脉造影术的患者免于CIN。
Contrast-induced nephropathy (CIN) is associated with increased morbidity, extended hospital stay, and higher costs. We compared an atorvastatin plus N-acetylcysteine (NAC) regimen with NAC alone in patients undergoing coronary angiography. A total of 130 patients (mean age 54 +/- 10; 77 men) undergoing coronary angiography were studied. Seven CIN cases occurred in the NAC group and 2 in the atorvastatin + NAC group; this difference was not significant. Baseline mean creatinine and estimated glomerular filtration rate (eGFR) were similar between the 2 groups, whereas after the procedure there was a significant creatinine decrease and eGFR increase in the atorvastatin + NAC group. Change in creatinine (baseline creatinine-creatinine after the procedure) was also significantly higher in patients taking statin plus NAC. Atorvastatin may be effective in protecting patients undergoing coronary angiography from CIN.